

RESEARCH PRICE CHARACTERISTICS OF VACCINES AGAINST INFLUENZA VIRUS

Streltsova T. V., Simonian L. S.

National University of Pharmacy, Kharkiv, Ukraine

liusine@ukr.net

Introduction. Each year, with the approach of a flu epidemic is increasing relevance of mass vaccination, especially of people of working age. Mass vaccination appears as one of the most effective means to combat the flu. This economic importance due to vaccination shall budgetary savings by reducing complications from influenza.

Thus the financial crisis and reduce the solvency of the population becomes particularly relevant study price characteristics vaccines. The analysis indicators index price growth for the vaccine can be used in the planning of the need for vaccination in preparation for epidemics of influenza.

Aim. Research of pricing characteristics of influenza virus vaccines

Materials and methods. Statistical comparative systematic and analytical methods and techniques of price analysis.

Results. The analysis of data of state registration of the SE "State Expert Center MoH Ukraine" was established that in 2016 registered 13 influenza virus vaccines (including release forms), production of European pharmaceutical companies, the price of which essentially depends on the exchange rate. Compared with 2007 the number of vaccines increased by 43.75%.

Registered in the pharmaceutical market of the vaccine presented in two forms release a fixed needle syringes with 84.6% and 15.4% of bottles and in four doses, vaccine dosed in disposable syringes with fixed needle 0.5 ml – 68.75% 0.1 ml – 6.25%; 0.25 ml – 12.5%, vials of 5 ml – 12.5%.

It should also be noted that domestic production of the vaccine are only 28.6% of the total, and vaccines imported - 71.4%.

Investigate to price characteristics of influenza virus vaccines we have selected vaccines recommended by the Ministry of Health of Ukraine for vaccination in epidsezoni 2015-2016 biennium. Vaksigryp suspension for injection in 0.5 ml №1 (SanofiPasteur S. A., France); Fluarix & trade suspension for injection in 0.5 ml №1 (GlaxoSmithKlineBiologicals, Germany); Influvac suspension for injection in 0.5 ml № 1 (AbbottBiologicals BV, The Netherlands).

Calculate the index price growth we have selected wholesale prices for vaccines against influenza viruses that were purchased for the budget years of 2007 - 2013. And presented on the site "online pharmacy" and "Marion".

In the absence of tenders in 2016 we were selected price-list distributors, operating in the domestic pharmaceutical market vaccines against influenza viruses.

Calculate price indices (lg) were carried out monitoring studies of average wholesale prices for vaccines against influenza viruses that were present in the domestic pharmaceutical market in the period 2007-2016. Thus, the value lg Vaksigryp the drug suspension for injection 0.5 ml №1 (SanofiPasteur S. A., France) in 2007 was 1.04 and in 2016 – 2.15. That is, the average price over the past year increased by 48.37%. The value of lg Influvac the vaccine suspension for injection in 0.5 ml № 1 (AbbottBiologicals BV, Netherlands) in 2007 amounted to 0.97, and in 2015 of 2.33, the price of the drug has increased by about 58.37%. Indicators lg the vaccine Fluarix & trade suspension for injection in 0.5 ml №1 (GlaxoSmithKlineBiologicals, Germany) were important in 2007 – 0.70, and in 2016 – 2.56, the price of study drug increased about 72.65%.

Conclusion. Given the fact that the domestic pharmaceutical market the vaccine recommended for vaccination only foreign, now becomes an important social and economic importance of the implementation of program activities of import substitution.

Registered in the pharmaceutical market of the vaccine presented in two forms release a fixed needle syringes with 84.6% and 15.4% of bottles and in four doses, vaccine dosed in disposable syringes with fixed needle 0.5 ml – 68.75% 0.1 ml – 6.25%; 0.25 ml – 12.5%, vials of 5 ml – 12.5%.

Thus, the value lg Vaksigryp the drug suspension for injection 0.5 ml №1 (SanofiPasteur S. A., France) in 2007 was 1.04 and in 2016 – 2.15. That is, the average price over the past year increased by 48.37%. The value of lg Influvac the vaccine suspension for injection in 0.5 ml № 1 (AbbottBiologicals BV, Netherlands) in 2007 amounted to 0.97, and in 2015 of 2.33, the price of the drug has increased by about 58.37%. Indicators lg the vaccine Fluarix & trade suspension for injection in 0.5 ml №1 (GlaxoSmithKlineBiologicals, Germany) were important in 2007 – 0.70, and in 2016 – 2.56, the price of study drug increased about 72.65%.

Thus, the results of our research of price characteristics vaccines have proved that today a priority national health care system and pharmacy in addressing the issue of mass vaccination against the influenza virus is to encourage domestic manufacturers to produce vaccines and the development of state programs of pharmaceutical software vaccines.